Candel Therapeutics Inc. (NASDAQ:CNDT) reached a 52‑week high of $13.96, trading at $13.93 at the time of reporting, just 1% below the peak. The market‑capitalization figure stood at roughly $1.06 billion.
Analyst coverage turned more bullish. Freedom Broker lifted its target price to $15.00, H.C. Wainwright maintained a buy rating with a $23.00 target, and Stifel initiated coverage with a buy recommendation and a $22.00 price objective.
The stock has surged 132.47% over the past year. InvestingPro’s proprietary metrics showed a 125% return over 12 months and a 153% gain in the last six months. In the day’s trading, the share price rose $0.68, or 5.11%.
Candel announced the start of its Phase III AURORA global trial for the gene‑therapy candidate aglatimagene besadenovec, aimed at patients with metastatic non‑squamous non‑small cell lung cancer. The trial will involve about 150 centers worldwide and compare the experimental combination therapy against standard chemotherapy.
In a parallel move, the company appointed Mark Sims as chief commercial officer, effective July 2026, to lead commercialization strategy for aglatimagene besadenovec in prostate cancer. Candel expects to file a biologics license application for the therapy in late 2026.
